Volume 29, Issue 2 (Spring 2023)
Intern Med Today 2023, 29(2): 81-86 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Halvani A, Rafatmagham S. Survival Analysis in Patients with Malignant Pleural Effusion. Intern Med Today 2023; 29 (2) :81-86
URL: http://imtj.gmu.ac.ir/article-1-4021-en.html
URL: http://imtj.gmu.ac.ir/article-1-4021-en.html
1- MD, Department of Internal Medicine, Yazd Medical Science Branch, Islamic Azad University, Yazd, Iran.
2- MD, Department of Internal Medicine, Fasa University of Medical Sciences, Fasa, Iran. ,r.sareh2012@gmail.com
2- MD, Department of Internal Medicine, Fasa University of Medical Sciences, Fasa, Iran. ,
Abstract: (72 Views)
Aims: The present study aimed to assess the survival of patients with malignant pleural effusion (MPE) and identify factors that impact prognosis. It is crucial to identify these factors and provide appropriate treatment for patients with lower survival rates in MPE.
Material & methods: This study analyzed the survival of patients with MPE in oncologic clinics in Yazd from 2011-2021. It was a descriptive cross-sectional study that utilized Kaplan-Meier analysis for survival analysis. The survival time was measured from pathological diagnosis to death. The data were analyzed in SPSS software (version 21).
Findings: The study involved 135 patients (mean age: 54.24; range: 22-65). Most patients were in their 6th and 7th decades, and only 6.7% of cases were under 40 years old. Regarding gender, 63 cases were male, and 72 subjects were female. The main causes of metastasis in MPE patients were lung cancer, breast cancer, and adenocarcinoma of unknown origin. Chemotherapy, followed by combination therapy, was the common treatment approach. Out of 135 patients, 109 cases passed away during the study. The average survival time was 21.67 months, with a 30% chance of 2-year survival and a 10% chance of 5-year survival. The study found no significant relationship between survival rate and gender or cause of the disease (mesothelioma or metastasis); nonetheless, age, treatment type, and malignancy type exhibited a significant relationship.
Conclusion:Timely diagnosis and appropriate treatment are crucial for improving patient survival, especially in the first two years. It is essential to prioritize screening, diagnosis, and treatment of low survival rate cancers, such as lung cancer, adenocarcinoma of unknown origin, and renal cell carcinoma.
Material & methods: This study analyzed the survival of patients with MPE in oncologic clinics in Yazd from 2011-2021. It was a descriptive cross-sectional study that utilized Kaplan-Meier analysis for survival analysis. The survival time was measured from pathological diagnosis to death. The data were analyzed in SPSS software (version 21).
Findings: The study involved 135 patients (mean age: 54.24; range: 22-65). Most patients were in their 6th and 7th decades, and only 6.7% of cases were under 40 years old. Regarding gender, 63 cases were male, and 72 subjects were female. The main causes of metastasis in MPE patients were lung cancer, breast cancer, and adenocarcinoma of unknown origin. Chemotherapy, followed by combination therapy, was the common treatment approach. Out of 135 patients, 109 cases passed away during the study. The average survival time was 21.67 months, with a 30% chance of 2-year survival and a 10% chance of 5-year survival. The study found no significant relationship between survival rate and gender or cause of the disease (mesothelioma or metastasis); nonetheless, age, treatment type, and malignancy type exhibited a significant relationship.
Conclusion:Timely diagnosis and appropriate treatment are crucial for improving patient survival, especially in the first two years. It is essential to prioritize screening, diagnosis, and treatment of low survival rate cancers, such as lung cancer, adenocarcinoma of unknown origin, and renal cell carcinoma.
Type of Study: Original |
Subject:
Internal Medicine
Received: 2023/12/16 | Accepted: 2024/02/13 | Published: 2024/03/5
Received: 2023/12/16 | Accepted: 2024/02/13 | Published: 2024/03/5
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |